QEL 001
Alternative Names: QEL-001Latest Information Update: 11 Jun 2024
At a glance
- Originator Quell Therapeutics
- Class CAR-T cell therapies; Gene therapies
- Mechanism of Action Immunologic cytotoxicity; Regulatory T-lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Liver transplant rejection
Most Recent Events
- 04 Jun 2024 Adverse events data from a phase-I/II clinical trials in Liver transplant rejection released by Quell Therapeutics
- 09 Jun 2023 Quell Therapeutics plans a first-in-human clinical trial for Liver transplant rejection in 2023
- 21 Jan 2022 Phase-I/II clinical trials in Liver transplant rejection (Treatment experienced) in United Kingdom (Parenteral) (NCT05234190)